bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
1996

bcl-2 and p53 in Prostate Cancer

Sample size: 77 publication Evidence: moderate

Author Information

Author(s): I Apakama, MC Robinson, NM Walter, RG Charlton, JA Royds, CE Fuller, DE Neal, FC Hamdy

Primary Institution: University Urology Unit, Newcastle upon Tyne

Hypothesis

The study investigates the significance of bcl-2 protein overexpression and p53 nuclear protein accumulation in predicting hormone resistance in prostate cancer.

Conclusion

The combined detection of p53 protein accumulation and bcl-2 overexpression may help predict hormone resistance in prostate cancer.

Supporting Evidence

  • 37 out of 77 cancers (48%) showed bcl-2 overexpression at diagnosis.
  • 20 out of 27 patients with bcl-2 overexpression treated with hormone manipulation had hormone-refractory disease (74%).
  • 14 out of 21 patients with p53 accumulation treated with hormones showed hormone resistance (66.6%).
  • 81.2% of patients with both bcl-2 overexpression and p53 accumulation had hormone-refractory disease.

Takeaway

This study looked at how two proteins, bcl-2 and p53, can help doctors understand if prostate cancer will resist hormone treatment.

Methodology

The study involved immunohistochemistry to assess bcl-2 and p53 expression in prostate cancer tissues from 77 men.

Limitations

The study did not collect tissue from hormonally treated men for ethical reasons.

Participant Demographics

Participants were 77 men aged 46 to 88 years (median 71 years) with histologically proven prostate cancer.

Statistical Information

P-Value

P<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication